1. Wang, Weijia, He, Shanzhi, Zhang, Wenli, Ma, Yupo, Yuan, Yong. 2024. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. In Annals of the rheumatic diseases, 83, 1304-1314. doi:10.1136/ard-2024-225785. https://pubmed.ncbi.nlm.nih.gov/38777376/
2. Shah, Nina, Chari, Ajai, Scott, Emma, Mezzi, Khalid, Usmani, Saad Z. 2020. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. In Leukemia, 34, 985-1005. doi:10.1038/s41375-020-0734-z. https://pubmed.ncbi.nlm.nih.gov/32055000/
3. Chae, Soo-Cheon, Yu, Ji-In, Oh, Gyung-Jae, Yang, Yun-Sik, Yun, Ki-Jung. 2009. Identification of single nucleotide polymorphisms in the TNFRSF17 gene and their association with gastrointestinal disorders. In Molecules and cells, 29, 21-8. doi:10.1007/s10059-010-0002-6. https://pubmed.ncbi.nlm.nih.gov/20016944/
4. Smith, Eric L, Harrington, Kim, Staehr, Mette, Sather, Blythe, Brentjens, Renier J. . GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. In Science translational medicine, 11, . doi:10.1126/scitranslmed.aau7746. https://pubmed.ncbi.nlm.nih.gov/30918115/
5. van de Donk, Niels W C J, Usmani, Saad Z, Yong, Kwee. . CAR T-cell therapy for multiple myeloma: state of the art and prospects. In The Lancet. Haematology, 8, e446-e461. doi:10.1016/S2352-3026(21)00057-0. https://pubmed.ncbi.nlm.nih.gov/34048683/
6. Firestone, Ross S, Socci, Nicholas D, Shekarkhand, Tala, Usmani, Saad Z, Chung, David J. . Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. In Blood, 144, 402-407. doi:10.1182/blood.2023023557. https://pubmed.ncbi.nlm.nih.gov/38728378/
7. Wong, Derek P, Roy, Nand K, Zhang, Keman, Caimi, Paolo, Parameswaran, Reshmi. 2022. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. In Nature communications, 13, 217. doi:10.1038/s41467-021-27853-w. https://pubmed.ncbi.nlm.nih.gov/35017485/
智鼠故事 
